RT @EvaHernandezGa9: Honored to present BREATHS trial in progress at #ASCO25! -first to investigate whether in-bedroom air filtration, when….

RT @lusignan_s: Despite our best efforts, without more robust built in evaluation, it is hard to know how effective lock downs and other no….

Our paper is open access and has been published by the Journal of Public Health. With thanks to our colleagues from the Usher Institute, UNCOVER | Applied Evidence Synthesis, University of Edinburgh who led the work with help from

These studies and interventions were implemented quickly during the pandemic, when they were most needed. However, to support future pandemic and public health emergencies decision-making, we need to improve the process of rapid high-quality evidence generation and evaluation.

Evidence certainty for most non-pharmacological interventions was very low or inconclusive. The best available evidence was for test & release strategies for case contacts (moderate certainty), which was suggestive of a protective effect. .

There was very large heterogeneity across study designs, settings, populations, reporting of intervention implementation and outcomes, comparators, and effect sizes. We had to summarize the findings across all studies and interventions narratively and using very long tables. .

We identified 97 studies (85 were modelling studies, 9 were observational, and 3 were RCTs). The studies reported data on effectiveness (as measured by effects on COVID-19 cases, transmission, hospitalizations & deaths) for 20 classes of non-pharmacological interventions!.

One of the largest and most heterogeneous systematic reviews I have ever worked on:.We aimed to examine the effectiveness of non-pharmacological interventions implemented in the UK during the COVID-19 pandemic. .

RT @JoachimSchork: Unlocking the full potential of your linear regression analysis starts with validating its suitability. Here’s a summary….

RT @cooltechtipz: Where has this been all my life?

Looking forward to the lecture: Meta-analysis of individual participant data in vaccine research by Associate Professor @MerrynVoysey at Rewley House on Thursday 20 June 2024, 17:30-18:30. If you'd like to attend, register here:.

Wow! I guess there are still a few more things that I need to do!.

RT @lusignan_s: Nice to see this review published It illustrates the need for more real world evidence studies to c….

Check out our latest paper on the generalisability of #kidney trials populations receiving #SGLT2 inhibitors. Less than 10% of UK primary care population with #CKD would be eligible for these trials. @OxPrimaryCare @ORCHID_Oxford @lusignan_s .

RT @EmbSpainUK: In Seville, at this time of the year, the Town Hall leaves the picked oranges under the fruit trees placed in the streets f….

I've just signed this petition. Will you add your name and share too?. via @38degrees.

How has the COVID-19 pandemic affected the delivery of preventive healthcare? ."Advice and support for smoking, and advice for weight, excess alcohol and physical inactivity have not returned to pre-pandemic levels.".@OxPrimaryCare @ORCHID_Oxford

There is no universally accepted means of defining or subdividing the #immunosuppressed. We investigated if excess #COVID mortality could risk-stratify immunosuppression:.@OxPrimaryCare @lusignan_s

RT @lusignan_s: Implementation of chronic kidney disease guidelines for SGLT2i Great to see @RCGP Research and Sur….

The cardiovascular & kidney benefits of #SGLT2 inhibitors in people with CKD are well established. Paradoxically, individuals at higher risk of adverse outcomes are less likely to receive SGLT2 inhibitor treatment. Our latest paper:.@clininf @lusignan_s.